NASDAQ$ONC
BeiGene Ltd-ADR · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
BeiGene's financial results for Q1 2020 were reported, highlighting the launch of tislelizumab in China and key milestones achieved.
BeiGene reported a decrease in total revenue primarily due to the lack of collaboration revenue and decreased product sales of ABRAXANE, REVLIMID and VIDAZA in China, which was partially offset by initial sales of tislelizumab in China and BRUKINSA in the United States. They launched tislelizumab in China and are managing the challenges of COVID-19 to maintain momentum in their development program.
- Launched tislelizumab in China in March 2020 for classical Hodgkin’s lymphoma patients.
- Received approval from China's NMPA for tislelizumab to treat locally advanced or metastatic urothelial carcinoma.
- Generated $52.06 million in product revenue.
- Transition activities for Amgen commercial oncology medicines in China are on track.
Headline financials
Revenue & EPS history
BeiGene · Revenue · Quarterly
$52.1M
Revenue by segment
BeiGene · $720K total across 1 segment · Q1 2020
- BRUKINSA$720K—100.0%
Forward guidance
This press release contains forward-looking statements regarding BeiGene's product candidates, approvals, clinical trials, data readouts, commercial product launches, and milestones.
Tailwinds
- Recent clinical data for BeiGene’s product candidates and approvals of its products
- The conduct of late-stage clinical trials and expected data readouts
- Additional planned commercial product launches
- The advancement of and anticipated clinical development, regulatory milestones and commercialization of BeiGene’s products and drug candidates
- BeiGene’s plans and the expected milestones under the caption “Recent Business Highlights and Upcoming Milestones”
Headwinds
- BeiGene's ability to demonstrate the efficacy and safety of its drug candidates
- The clinical results for its drug candidates, which may not support further development or marketing approval
- Actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval
- BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved
- The impact of the COVID-19 pandemic on the Company’s clinical development, commercial and other operations
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
-0.1%
Avg return
Earnings day
+0.1%
Avg return
5 days after
-2.0%
Avg return
30 days after
40%
16 / 40 earnings
Positive
+15.9%
Q4 2023
Best reaction
-9.6%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.3% | +4.3% | -9.4% | |
| Q4 2025 | -8.5% | -15.7% | -19.6% | |
| Q3 2025 | +3.4% | +6.9% | +0.5% | |
| Q1 2025 | -3.9% | -3.5% | +5.8% | |
| Q4 2024 | +7.5% | -0.7% | +3.2% | |
| Q3 2024 | +1.4% | -4.5% | +1.4% | |
| Q2 2024 | +6.8% | +10.9% | +11.7% | |
| Q1 2024 | -2.0% | -2.2% | -4.9% | |
| Q4 2023 | +15.9% | +6.4% | -0.0% | |
| Q3 2023 | -0.5% | +0.7% | -12.6% | |
| Q2 2023 | -0.3% | -9.2% | +1.2% | |
| Q1 2023 | -5.7% | -7.3% | -14.2% | |
| Q4 2022 | +4.2% | +11.9% | +2.9% | |
| Q3 2022 | -0.2% | +7.3% | +4.2% | |
| Q2 2022 | +14.6% | +16.4% | -1.7% | |
| Q1 2022 | -9.6% | -11.9% | -12.9% | |
| Q4 2021 | -2.5% | -0.8% | -10.8% | |
| Q3 2021 | -2.3% | -1.1% | -15.9% | |
| Q2 2021 | -6.3% | -8.1% | -2.0% | |
| Q1 2021 | +2.2% | +5.4% | +15.7% | |
| Q4 2020 | -4.4% | -8.5% | -3.0% | |
| Q3 2020 | -3.6% | -7.2% | -26.8% | |
| Q2 2020 | -2.9% | -7.7% | +5.8% | |
| Q1 2020 | +1.0% | +6.0% | +9.6% | |
| Q4 2019 | -2.3% | -3.2% | -21.8% | |
| Q3 2019 | +2.9% | +3.4% | -6.5% | |
| Q2 2019 | +1.6% | +3.9% | -7.8% | |
| Q1 2019 | +14.2% | +13.6% | +4.3% | |
| Q4 2018 | -2.1% | +8.4% | -5.7% | |
| Q3 2018 | +1.4% | -11.2% | +10.4% | |
| Q2 2018 | -3.7% | -4.4% | -4.7% | |
| Q1 2018 | -5.2% | +4.3% | +20.9% | |
| Q4 2017 | -4.8% | +0.3% | +11.3% | |
| Q3 2017 | -5.5% | -0.0% | +10.4% | |
| Q2 2017 | -7.3% | -9.0% | -7.4% | |
| Q1 2017 | -1.3% | +0.7% | +3.9% | |
| Q4 2016 | -2.8% | -4.1% | -3.1% | |
| Q3 2016 | -4.7% | +7.4% | -19.5% | |
| Q2 2016 | +0.8% | +6.0% | +11.0% | |
| Q4 2015 | +5.9% | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro